我国肺癌筛查现状与展望

doi:10.16150/j.1671-2870.2018.05.001

摘要/Abstract

中图分类号:

R734.1

韩宝惠, 沈胤晨. 我国肺癌筛查现状与展望[J]. 诊断学理论与实践, 2018, 17(05): 487-489.

[1] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clinm,2016,66(2):115-132.
[2] MMurakami S, Ito H, Tsubokawa N, et al.Prognostic va-lue of the new IASLC/ATS/ERS classification of clinical stage IA lung adenocarcinoma[J]. Lung Cancer,2015,90(2):199-204.
[3] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017[J]. CA Cancer J Clin,2017,67(1):7-30.
[4] National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening[J]. N Engl J Med,2011,365(5):395-409.
[5] Ru Zhao Y, Xie X, de Koning HJ, et al. NELSON lung cancer screening study[J]. Cancer Imaging,2011,11,S79-S84.
[6] International Early Lung Cancer Action Program Investigators, Henschke CI, Yankelevitz DF, et al. Survival of patients with stage I lung cancer detected on CT scree-ning[J]. N Engl J Med,2006,355(17):1763-1771.
[7] Gulati S, Mulshine JL.Lung cancer screening guidelines: common ground and differences[J]. Transl Lung Cancer Res,2014,3(3):131-138.
[8] Zhou Q, Fan Y, Wu N, et al.Demonstration program of population-based lung cancer screening in China: Rationale and study design[J]. Thorac Cancer,2014,5(3):197-203.
[9] Zhou QH, Fan YG, Bu H, et al.China national lung cancer screening guideline with low-dose computed tomography (2015 version)[J]. Thorac Cancer,2015,6(6):812-818.
[10] Zhou Q, Fan Y, Wang Y, et al.China National Lung Cancer Screening Guideline with Low-dose Computed ?Tomography (2018 version)[J]. Zhongguo Fei Ai Za Zhi,2018,21(2):67-75.
[11] Zheng R, Zeng H, Zuo T, et al.Lung cancer incidence and mortality in China, 2011[J]. Thorac Cancer,2016,7(1):94-99.
[12] He YT, Zhang YC, Shi GF, et al.Risk factors for pulmonary nodules in north China: A prospective cohort study[J]. Lung Cancer,2018,120:122-129.
[13] Tang W, Wu N, Huang Y, et al.Results of low-dose computed tomography (LDCT) screening for early lung cancer: prevalence in 4 690 asymptomatic participants[J]. Zhonghua Zhong Liu Za Zhi,2014,36(7):549-554.
[14] Yang W, Qian F, Teng J, et al.Community-based lung cancer screening with low-dose CT in China: Results of the baseline screening[J]. Lung Cancer,2018,117:20-26.
[15] Patz EF Jr, Pinsky P, Gatsonis C, et al.Overdiagnosis in low-dose computed tomography screening for lung cancer[J]. JAMA Intern Med,2014,174(2):269-274.
[16] Santarpia M, Liguori A, D'Aveni A, et al. Liquid biopsy for lung cancer early detection[J]. J Thorac Dis,2018, 10(Suppl 7):S882-S897.
[17] Ooki A, Maleki Z, Tsay JJ, et al.A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non-Small Cell Lung Cancer and Serum DNA[J]. Clin Cancer Res,2017,23(22):7141-7152.
[18] Ostrow KL, Hoque MO, Loyo M, et al.Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR[J]. Clin Cancer Res,2010,16(13):3463-3472.
[19] Sozzi G, Roz L, Conte D, et al.Plasma DNA quantification in lung cancer computed tomography screening: five-year results of a prospective study[J]. Am J Respir Crit Care Med,2009,179(1):69-74.
[20] Ilie M, Hofman V, Long-Mira E, et al."Sentinel" circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease[J]. PLoS One,2014,9(10):e111597.
[21] Jin X, Chen Y, Chen H, et al.Evaluation of Tumor-Derived Exosomal miRNA as Potential Diagnostic Biomar-kers for Early-Stage Non-Small Cell Lung Cancer Using Next-Generation Sequencing[J]. Clin Cancer Res,2017,23(17):5311-5319.
[22] Best MG, Sol N, Kooi I, et al.RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics[J]. Cancer Cell,2015,28(5):666-676.

我国肺癌筛查现状与展望

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	孙艳艳, 兰信堂. 肺癌颅脑转移患者接受放射治疗后前庭功能受损1例[J]. 诊断学理论与实践, 2022, 21(05): 632-634.
[2]	吴歆, 耿旭强, 徐沪济. 多基因风险评分在复杂性状疾病中的应用进展[J]. 诊断学理论与实践, 2020, 19(05): 540-543.
[3]	杜海磊, 陈聆, 罗方秀, 李勇, 程齐俭, 朱良纲, 杭钧彪. Beclin-1和Bcl-2表达与非小细胞肺癌患者病理特征及预后间关系的研究[J]. 诊断学理论与实践, 2020, 19(03): 258-263.
[4]	王晓妍, 潘丽娜, 高蓓莉, 徐志红, 胡家安. 影像组学及影像基因组学在肺癌诊疗中的应用进展[J]. 诊断学理论与实践, 2019, 18(06): 711-714.
[5]	刘海霞, 瞿介明. 肺部微生态及其与肺癌关系的研究进展[J]. 诊断学理论与实践, 2019, 18(05): 496-502.
[6]	王晓斐, 高蓓莉. 肺癌免疫治疗标志物研究进展认识[J]. 诊断学理论与实践, 2018, 17(05): 494-498.
[7]	张国桢, 蔡庆, 张伟强. 早期微小肺腺癌CT影像与病理的相关性[J]. 诊断学理论与实践, 2018, 17(05): 490-493.
[8]	顾圣佳, 曹琪琪, 严福华, 杨文洁. 双能CT在非小细胞肺癌非手术治疗疗效评估中的应用价值[J]. 诊断学理论与实践, 2018, 17(05): 526-532.
[9]	张新, 张新宇. 支气管冲洗液基因检测在肺癌诊治中的价值[J]. 诊断学理论与实践, 2018, 17(05): 508-511.
[10]	马韵芳, 潘丽娜, 张培培, 何清, 徐志红, 胡家安. 人类表皮生长因子受体2基因扩增的非小细胞肺癌一例报告[J]. 诊断学理论与实践, 2018, 17(04): 462-465.
[11]	杨文洁, 严福华. 2015版《低剂量螺旋CT肺癌筛查专家共识》和《肺亚实性结节影像处理专家共识》解读[J]. 诊断学理论与实践, 2017, 16(01): 32-37.
[12]	陈刚, 黄银琼,. 糖尿病及糖尿病高风险人群的早期筛查与诊断[J]. 诊断学理论与实践, 2016, 15(04): 339-341.
[13]	宗晓福, 仇玉平, 张文娟, 俞同福,. 肺黏液性腺癌的临床及CT表现和病理特点[J]. 诊断学理论与实践, 2015, 14(04): 353-356.
[14]	应建明, 邱田,. 肺癌表皮生长因子基因突变和间变性淋巴瘤激酶融合基因的规范化检测[J]. 诊断学理论与实践, 2013, 12(06): 591-595.
[15]	谢静, 王华枫, 袁菲, 孙月芳, 吴丽莉, 金晓龙,. 实时荧光定量PCR法检测非小细胞肺癌EGFR基因突变的总结分析[J]. 诊断学理论与实践, 2013, 12(06): 606-609.